GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.
IPO Year: 2020
Exchange: NASDAQ
Website: goodrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $5.00 | Neutral | Mizuho |
| 8/9/2024 | $10.00 | Outperform → Strong Buy | Raymond James |
| 5/23/2024 | $8.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 5/16/2024 | $10.00 | Mkt Perform → Outperform | Raymond James |
| 4/10/2024 | $9.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/25/2024 | $7.50 → $10.00 | Equal Weight → Overweight | Wells Fargo |
| 3/1/2024 | $7.00 → $10.00 | Neutral → Overweight | JP Morgan |
| 2/26/2024 | $8.00 | Outperform | Leerink Partners |
| 1/2/2024 | $8.00 → $4.50 | Buy → Underperform | BofA Securities |
| 8/10/2023 | $9.50 | Neutral → Buy | DA Davidson |
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel
Company working with Hy-Vee as launch partner to simplify how consumers get their medications through the GoodRx platform GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced a new e-commerce experience for retail pharmacies that improves how consumers get their medications via the GoodRx platform. The company is launching the experience with Midwest-based retailer Hy-Vee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250403717682/en/GoodRx e-commerce experience Now, when a person searches for their medication on GoodRx and selects Hy-Vee as their preferred pharmacy, the system will che
Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy
Women Spent $8.8 Billion More than Men in 2024, with Women Ages 18-44 Facing the Steepest Out-of-Pocket Cost Disparity GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today released a new report, The Prescription Drug Gender Divide, detailing how women shoulder a significantly greater out-of-pocket cost burden than men. The data shows that in 2024, women spent $8.8 billion – or 30% – more than men on out-of-pocket prescription costs. Combined with the common responsibilities of managing a career, family planning, and caregiving, women are left frustrated with the financial pressure required to maintain their health. Though the "pink tax" is often thought abo
Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr
HITRUST certification validates that GoodRx is operating leading security practices to protect sensitive information GoodRx (NASDAQ:GDRX), the leading medication savings platform in the U.S., today announced its drug savings platform residing with Amazon Web Services (AWS) has earned certified status for 2025 by HITRUST for information security. This milestone underscores GoodRx's dedication to safeguarding data and maintaining specific standards of cybersecurity in healthcare. HITRUST i1 Certification demonstrates that GoodRx's drug savings platform is leveraging a set of curated controls to protect against current and emerging threats. The HITRUST i1 Validated Assessment and Certifica
Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Thursday, February 27, 2025. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations websit
Former GoodRx Interim CEO brings a deep understanding of the GoodRx business and extensive leadership experience to his role as Co-Chair of the Board GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced that Scott Wagner has joined its Board of Directors, effective January 21, 2025. Mr. Wagner, who recently led GoodRx as its Interim Chief Executive Officer from April 2023 to January 2025, has been appointed as Co-Chair of the Board and will serve alongside existing Co-Chair Trevor Bezdek. Wagner joins the Board with more than 25 years of executive leadership experience, including his im
GoodRx for Pets leverages new integrated e-commerce capabilities to create a seamless user experience for accessing essential pet medications and information GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced a new GoodRx for Pets experience that provides a more affordable and convenient way for Americans to access pet medications. Through GoodRx for Pets, pet owners can find savings and have pet medications delivered right to their door. GoodRx for Pets provides a seamless experience for pet owners, combining convenience, affordability, and accessibility in one place. This press release features multimedia. View the full release here: https://ww
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
S-8 - GoodRx Holdings, Inc. (0001809519) (Filer)
10-K - GoodRx Holdings, Inc. (0001809519) (Filer)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
SCHEDULE 13G - GoodRx Holdings, Inc. (0001809519) (Subject)
8-K - GoodRx Holdings, Inc. (0001809519) (Filer)
SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel
Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Thursday, February 27, 2025. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations websit
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $195.3 million Net income of $4.0 million; Net income margin of 2.0% Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4% Adjusted EBITDA1 of $65.0 million; Adjusted EBITDA Margin1 of 33.3% Net cash provided by operating activities of $86.9 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "In a world where there is increasing attention on medicin
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://inve
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Income1 of $32.4 million; Adjusted Net Income Margin1 of 16.1% Adjusted EBITDA1 of $65.4 million; Adjusted EBITDA Margin1 of 32.6% Net cash provided by operating activities of $9.7 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "We're proud of the progress we're making against
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://inve
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024. First Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $197.9 million Net loss of $1.0 million; Net loss margin of 0.5% Adjusted Net Income1 of $32.6 million; Adjusted Net Income Margin1 of 16.5% Adjusted EBITDA1 of $62.8 million; Adjusted EBITDA Margin1 of 31.7% Net cash provided by operating activities of $42.6 million Exited the quarter with approximately 8 million consumers of prescription-related offerings2 "I'm encouraged by the strides we've m
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., today announced it will hold its first Investor Day on May 15, 2024, in New York City. The event will begin at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). The event will feature presentations by GoodRx's Interim CEO, Scott Wagner; CFO, Karsten Voermann; as well as other leaders from across the Company and will include an overview of the company's business drivers and its strategy for long-term growth, followed by a Q&A session. A link to access the live webcast, as well as any related materials, will be available on GoodRx's investor relations website at ht
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., today announced it will release its first quarter 2024 financial results before U.S. markets open on Thursday, May 9, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://i
Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00
Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00
RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously
Raymond James upgraded GoodRx from Mkt Perform to Outperform and set a new price target of $10.00
KeyBanc Capital Markets upgraded GoodRx from Sector Weight to Overweight and set a new price target of $9.00
Wells Fargo upgraded GoodRx from Equal Weight to Overweight and set a new price target of $10.00 from $7.50 previously
JP Morgan upgraded GoodRx from Neutral to Overweight and set a new price target of $10.00 from $7.00 previously
Leerink Partners initiated coverage of GoodRx with a rating of Outperform and set a new price target of $8.00
BofA Securities downgraded GoodRx from Buy to Underperform and set a new price target of $4.50 from $8.00 previously
DA Davidson upgraded GoodRx from Neutral to Buy and set a new price target of $9.50
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)
SC 13G - GoodRx Holdings, Inc. (0001809519) (Subject)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
4 - GoodRx Holdings, Inc. (0001809519) (Issuer)
3 - GoodRx Holdings, Inc. (0001809519) (Issuer)
Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy
Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca
WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Sarah Griffis as the Company's new Chief Technology Officer, effective January 6, 2025. "I am thrilled to welcome Sarah as our new CTO. She has great experience not just building and leading engineering and tech teams, but also operating in regulated industries like ours," said Doug Francis, Chief Executive Officer at Weedmaps. "I look forward to partnering with her and the rest of our tech org to continue delivering innovative and best-in-class technology solutions to our customers." Prior to joining W
Wendy Barnes, Current CEO of RxBenefits, Brings Extensive Healthcare Management Experience to the Company GoodRx Holdings, Inc. (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Wendy Barnes has been appointed as President and Chief Executive Officer, effective January 1, 2025. Wendy brings more than 30 years of leadership experience across the pharmacy and medical benefit industry to her new role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216730604/en/Wendy Barnes (Photo: Business Wire) Wendy will join GoodRx following her role as CEO of RxBenefits, where she led the company in
Former Chief Financial Officer of The Honest Company brings over 25 years of experience across retail and consumer brands GoodRx (NASDAQ:GDRX), a leading resource for healthcare savings and information, today announced the election of Kelly J. Kennedy to its Board of Directors. Kennedy will serve as a member of the Board's audit committee and fill the seat left vacant by Jacqueline Kosecoff earlier this year. With over 25 years of experience serving in senior financial roles for leading retail and consumer brands, Kennedy brings extensive experience overseeing risk assessment management and financial reporting at large public companies. Currently, Kennedy serves as Chief Financial Offic
Amino Health, the leading digital healthcare navigation company, today announced the appointment of John Asalone to the role of Chief Executive Officer. He succeeds David Vivero, the company's visionary founder and CEO, who steps into a new role as Chairman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231213064342/en/John Asalone, Amino Health CEO (Photo: Business Wire) Asalone, who joined Amino this past August as COO, is a seasoned executive with 20 years of experience scaling software and marketplace companies. Previously the SVP of Growth Verticals at GoodRx (NASDAQ:GDRX), Asalone specializes in bringing consumer-grade ex
Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv
Gemmell to co-lead Pharma Manufacturer Solutions business, oversee GoodRx Health and Provider Mode GoodRx (NASDAQ:GDRX), a leading resource for healthcare savings and information, today announced the appointment of Dorothy Gemmell as Chief Commercial Officer, effective July 3, 2023. Gemmell will work closely with Aaron Crittenden, newly appointed Chief Revenue Officer, and together they will lead the company's Pharma Manufacturer Solutions business, which provides solutions for pharmaceutical and medical device companies. Gemmell brings with her a strong track record leading high-growth teams and building trusted, market-leading healthcare companies that provide solutions to pharmaceuti
DocGo (NASDAQ:DCGO), a leading provider of last-mile mobile health services, today announced that it has appointed veteran human resources executive Vina Leite, MS, to its Board of Directors. Ms. Leite brings to the DocGo Board more than two decades of leadership, with experience transforming technology-driven high growth and Fortune 500 organizations by closely aligning human resources with corporate goals to achieve optimal outcomes. The company also announced key leadership promotions that will be effective December 31, 2022. "We are very pleased to have someone with Vina's experience and track record join our Board at this time," stated Stan Vashovsky, Chief Executive Officer and Chair
The company bolsters its leadership team with experienced mission-driven executives GoodRx (NASDAQ:GDRX), a leading consumer-focused digital healthcare platform, today announced it has made key leadership appointments to support the company's scaling business and accelerate innovation to bring more affordable and convenient healthcare to consumers across the country. Raj Beri will join GoodRx as the company's first ever Chief Operating Officer (COO) from Uber, where he served as Vice President of Grocery and New Verticals, overseeing the company's non-restaurant and last mile delivery businesses across global markets. With more than 20 years in the business operations space, Raj will lead